Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Amit Sanyal, MD: A Clinician’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Dec
11
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo